Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 16, 2021 at 06:31 am
Share
Sigyn Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 441,818 compared to USD 175,911 a year ago. Net loss was USD 649,861 compared to USD 260,396 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.52 a year ago. For the half year, operating loss was USD 843,915 compared to USD 368,890 a year ago. Net loss was USD 1.111 million compared to USD 511,578 a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 1.02 a year ago.
Sigyn Therapeutics, Inc. is a development-stage company. The Company is focused on creating therapeutic solutions that address unmet needs in global health. The Company's product candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Its treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis.
SIGN THERPAR 